# Spectrum Pharmaceuticals, Inc clinical trials: 60 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials with Spectrum Pharmaceuticals, Inc as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Spectrum Pharmaceuticals, Inc: 60 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/spectrum-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| May 18, 2022 | NCT05378763 | A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations | Spectrum Pharmaceuticals, Inc | Phase 3 | Suspended | NSCLC | 268 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05378763) |
| July 29, 2021 | NCT04981704 | A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of... | Spectrum Pharmaceuticals, Inc | Phase 1 | Completed | Healthy | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04981704) |
| September 30, 2020 | NCT04570423 | A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated... | Spectrum Pharmaceuticals, Inc | Phase 2 | Recruiting | Solid Tumors, Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04570423) |
| June 18, 2020 | NCT04436562 | Study of the Absorption, Metabolism, and Excretion Following a Single Dose of \[14C\]-Poziotinib in Healthy Male Subjects | Spectrum Pharmaceuticals, Inc | Phase 1 | Completed | Healthy | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04436562) |
| May 26, 2020 | NCT04402008 | Study of Poziotinib in Japanese Patients With NSCLC | Spectrum Pharmaceuticals, Inc | Phase 1/2 | Terminated | NSCLC | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04402008) |
| December 5, 2019 | NCT04187898 | Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer | Spectrum Pharmaceuticals, Inc | Phase 1 | Completed | Neutropenia, Breast Cancer | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04187898) |
| November 21, 2019 | NCT04172597 | A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2)... | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04172597) |
| January 15, 2019 | NCT03804515 | A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib | Spectrum Pharmaceuticals, Inc | Phase 1 | Terminated | Solid Tumor | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03804515) |
| November 16, 2018 | NCT03744715 | A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | NSCLC, Breast Cancer | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03744715) |
| February 12, 2018 | NCT03429101 | A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer | Spectrum Pharmaceuticals, Inc | Phase 1 | Terminated | Breast Cancer | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03429101) |
| October 24, 2017 | NCT03318939 | Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | NSCLC | 648 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03318939) |
| July 21, 2017 | NCT03224182 | A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor... | Spectrum Pharmaceuticals, Inc | Phase 3 | Terminated | Bladder Cancer | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03224182) |
| May 2, 2017 | NCT03135951 | Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy | Spectrum Pharmaceuticals, Inc | Phase 1 | Completed | Breast Cancer, Pharmacokinetics | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03135951) |
| November 2, 2016 | NCT02953340 | SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide | Spectrum Pharmaceuticals, Inc | Phase 3 | Completed | Neutropenia, Breast Cancer | 237 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02953340) |
| July 28, 2016 | NCT02847949 | A Study of IGN002 for Refractory NHL | Spectrum Pharmaceuticals, Inc | Phase 1 | Withdrawn | NHL | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02847949) |
| January 20, 2016 | NCT02659514 | Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer | Spectrum Pharmaceuticals, Inc | Phase 2 | Completed | Breast Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02659514) |
| December 31, 2015 | NCT02643420 | SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE) | Spectrum Pharmaceuticals, Inc | Phase 3 | Completed | Neutropenia, Breast Cancer | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02643420) |
| September 30, 2015 | NCT02563561 | A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT) | Spectrum Pharmaceuticals, Inc | Phase 3 | Terminated | Bladder Cancer | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02563561) |
| August 10, 2015 | NCT02519270 | Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects | Spectrum Pharmaceuticals, Inc | Phase 1 | Terminated | Non-Hodgkin Lymphoma | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02519270) |
| January 23, 2013 | NCT01773785 | Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | Biliary Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01773785) |
| December 4, 2012 | NCT01741155 | Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | Non Small Cell Lung Cancer (NSCLC) | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01741155) |
| November 12, 2012 | NCT01724866 | Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer | Spectrum Pharmaceuticals, Inc | Phase 2 | Completed | Neutropenia | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01724866) |
| August 10, 2012 | NCT01662102 | Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta) | Spectrum Pharmaceuticals, Inc | Phase 3 | Terminated | Follicular Lymphoma | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01662102) |
| April 30, 2012 | NCT01587144 | Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM) | Spectrum Pharmaceuticals, Inc | Phase 2 | Terminated | Glioblastoma Multiforme | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01587144) |
| March 22, 2012 | NCT01560884 | Study to Assess the Safety and the Phosphate Binding Capacity of Renazorb | Spectrum Pharmaceuticals, Inc | Phase 1 | Completed | Safety, Phosphate Binding Capacity | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01560884) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 16 |
| Phase 1/2 | 4 |
| Phase 2 | 21 |
| Phase 3 | 18 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 30 |
| Terminated | 24 |
| Withdrawn | 4 |
| Recruiting | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 9 |
| Lymphoma, Non-Hodgkin | 7 |
| Urinary Bladder Neoplasms | 7 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Neutropenia | 4 |
| Lymphoma | 4 |
| Neoplasms | 4 |
| Lymphoma, Follicular | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Leukemia | 3 |
| Lymphoma, Large B-Cell, Diffuse | 3 |
| Lymphoma, Mantle-Cell | 3 |
| Lung Neoplasms | 3 |
| Non-Muscle Invasive Bladder Neoplasms | 3 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Neoplasm Metastasis | 2 |
| Brain Neoplasms | 2 |
| Recurrence | 2 |
| Hodgkin Disease | 2 |
| Prostatic Hyperplasia | 2 |
| Small Cell Lung Carcinoma | 1 |
| Ovarian Neoplasms | 1 |
| Lymphoma, B-Cell | 1 |
| Lymphoproliferative Disorders | 1 |
| Lymphoma, T-Cell | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Mediterranean restaurants in the United States](https://specstream.ai/data/businesses/mediterranean-restaurants/united-states)
- [Wineries in the United States](https://specstream.ai/data/businesses/wineries/united-states)
- [Fire protection companies in the United States](https://specstream.ai/data/businesses/fire-protection-companies/united-states)
- [Puerto Rican restaurants in the United States](https://specstream.ai/data/businesses/puerto-rican-restaurants/united-states)
- [Building supply stores in the United States](https://specstream.ai/data/businesses/building-supply-stores/united-states)
